Safety of plasma-derived factor concentrates

Summary

Elaborate measures for donor selection and the production of clotting factor concentrates have led to a high safety standard of these products. A multimodal approach to eliminate unwanted contents has been established by strict screening of possible donors and various inactivation procedures within the production process. The systematic registration of adverse events shows very few allergic and nonallergic reactions to plasma derived clotting factor concentrates. In none of the registered cases transmission of infections could be verified. The worldwide registration of such adverse events is not yet sufficiently established, since adequate structures are lacking in some countries. According to estimates, far less than half of occurring adverse events are registered in Germany. A European solution in the form of an official register is about to be introduced.

Keywords

Plasma products - pharmacovigilance - inactivation process - donor screening

• References

• 1 Barletta JF, Ahrens CL, Tyburski JG. et al. A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma 2005; 58: 646-51.
• 2 Bonik K, Muller HG, Boeder H. Production of essential blood plasma preparations. Pharm Unserer Zeit 2006; 35: 29-38.
• 3 Bundesärztekammer.. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Köln: Deutscher Ärzte-Verlag; 2005
• 4 Chowdhury P, Saayman AG, Paulus U. et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125: 69-73.
• 5 De Jonge J, Groenland TH, Metselaar HJ. et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 2002; 94: 1127-31.
• 6 Gesetz über den Verkehr mit Arzneimitteln in der Fassung vom 11.12.1998 einschließlich des 14.. AMG-ÄndG aus: Arzneimittelrecht 6. Aufl. Bonn: Arzneimittel Info Service-AIS; 2005
• 7 Grundman C, Plesker R, Kusch M. et al. Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: in vitro and in vivo evidence. Thromb Haemost 2005; 94: 1338-9.
• 8 Graul A, Keller-Stanislawski B. Paul-Ehrlich-Institut.. Hämovigilanz von Blutkomponenten. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 1999; 42: 143-9.
• 9 Haschberger B, Waterkamp A, Heiden M. et al. Bericht zur Meldung nach §21 TFG für die Jahre 2001 und 2002. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005; 48: 99-119.
• 10 Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95: S13-17.
• 11 Llewelyn CA, Hewitt PE, Knight RS. et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
• 12 O’Shaughnessy DF, Atterbury C, Bolton Maggs P. et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
• 13 Peden AH, Head MW, Ritchie DL. et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.
• 14 Soucie JM, Robertson BH, Bell BP. et al. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573-9.
• 15 Stanworth SJ, Brunskill SJ, Hyde CJ. et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126: 139-52.
• 16 Yarranton H, Cohen H, Pavord SR. et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003; 121: 778-85.
• 17 Yee TT, Cohen BJ, Pasi KJ. et al. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93: 457-9.
• 18 Youssef WI, Salazar F, Dasarathy S. et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003; 98: 1391-4.
• 19 Zumberg MS, Waples JM, Kao KJ. et al. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol 2000; 64: 59-63.